Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Period	Debt/Equity
2018-12-31	0.06
2019-12-31	0.04
2020-12-31	0.24
2021-12-31	0.36
2022-12-31	0.53
2023-12-31	0.80
2024-12-31	1.23

	A	B	C	D
1	Symbol	Price	Change	Volume
2	KOD	$41.94	+0.36%	0.69M
3
4
5

Kodiak Sciences Inc (KOD) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Kodiak Sciences Inc Data in Excel

More KOD Financial Data